Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.58 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.58 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL12506247 | 0.98 | CHRM1 (0.56) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Propionic Acid SCHEMBL23044732 | 0.90 | CHRM1 (0.48) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL188001 | 0.84 | CHRM1 (0.60) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL31591104 | 0.84 | CHRM1 (0.60) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL6001765 | 0.84 | CHRM1 (0.60) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL28722632 | 0.82 | CHRM1 (0.58) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL28778365 | 0.82 | CHRM1 (0.61) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL2359243 | 0.80 | CHRM1 (0.59) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL671359 | 0.80 | TP53 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| Acetylcholine SCHEMBL27614905 | 0.79 | CHRM1 (0.73) | CHRM1CHRM3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551441-B2 | Water soluble silicon-containing granulate | BIO MINERALS NV (BE) | 2026-02-17 | — | — | US | claimed |
| US-20260026538-A1 | COMPOSITIONS COMPRISING CHOLINE AND OMEGA-3 FATTY ACID TO NUTRITIONALLY ENHANCE FOOD PRODUCTS | INGENUITY FOODS, INC. (US) | 2026-01-29 | — | — | US | claimed |
| US-12426615-B2 | Compositions comprising choline and omega-3 fatty acid to nutritionally enhance food products | INGENUITY FOODS, INC. (US) | 2025-09-30 | — | — | US | claimed |
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| WO-2025052161-A1 | SUBSTRATE AND METHOD | IAMFLUIDICS HOLDING B.V. (NL) | 2025-03-13 | — | — | WO | claimed |
| CN-119139230-A | Ionic liquid microemulsion and application thereof in external preparation drug-carrying matrix | 重庆医科大学 | 2024-12-17 | — | — | CN | claimed |
| US-20240408130-A1 | Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps | BIO MINERALS N.V. (BE) | 2024-12-12 | — | — | US | claimed |
| CN-119059544-A | Method for preparing spherical Mg-Al-LDH by regulating spherical Mg-Al-LDH and high Wen Fanxiang ionic liquid microemulsion system | 河南农业大学 | 2024-12-03 | — | — | CN | claimed |
| CN-116836098-B | Method for extracting and purifying astaxanthin from fermentation broth | 山东福瑞达生物科技有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20240138403-A1 | Synergistic Combinations for Reducing Volatility of Auxin Herbicides | ETHOX CHEMICALS, LLC | 2024-05-02 | — | — | US | claimed |
| US-10322098-B2 | Composition for use in the treatment of intervertebral disc-related pain | STAYBLE THERAPEUTICS AB (SE) | 2019-06-18 | — | — | US | claimed |
| EP-3270908-B1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL MISALIGNMENT | STAYBLE THERAPEUTICS AB (SE) | 2019-04-17 | — | — | EP | claimed |
| US-20180280327-A1 | COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN | STAYBLE THERAPEUTICS AB (SE) | 2018-10-04 | — | — | US | claimed |
| US-10080729-B2 | Composition for use in the treatment of intervertebral misalignment | STAYBLE THERAPEUTICS AB (SE) | 2018-09-25 | — | — | US | claimed |
| US-20180169041-A1 | COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN | STAYBLE THERAPEUTICS AB (SE) | 2018-06-21 | — | — | US | claimed |
| US-20180071234-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL MISALIGNMENT | STAYBLE THERAPEUTICS AB (SE) | 2018-03-15 | — | — | US | claimed |
| EP-3270908-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL MISALIGNMENT | STAYBLE THERAPEUTICS AB (SE) | 2018-01-24 | — | — | EP | claimed |
| EP-3119386-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN | STAYBLE THERAPEUTICS AB (SE) | 2017-01-25 | — | — | EP | claimed |
| WO-2016150825-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL MISALIGNMENT | STAYBLE THERAPEUTICS AB (SE) | 2016-09-29 | — | — | WO | claimed |
| WO-2015140320-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC-RELATED PAIN | ENCUBATOR AB (SE) | 2015-09-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551441-B2 | Water soluble silicon-containing granulate | SI, GIPR, VIP | CHRM1 230/4885CHRM3 459/4885CHRM2 432/4885 |
| US-20260026538-A1 | COMPOSITIONS COMPRISING CHOLINE AND OMEGA-3 FATTY ACID TO NUTRITIONALLY ENHANCE FOOD PRODUCTS | ELOVL3, ELOVL6, ELOVL1 | CHRM1 901/4885CHRM3 559/4885CHRM2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.